• Enrollment continues in Phase 1 dose-escalation trial, IMMUNICY-1, for allogeneic shRNA-based CAR T lead product candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma (MMr/r)
• The U.S. Food and Drug Administration (FDA) has lifted the clinical hold of the allogeneic CAR T product candidate, CYAD-101, based on the T-cell inhibitor (TIM) molecule for metastatic colorectal cancer (mCRC). ).
• The Company plans to focus more on collaborations related to the large intellectual property portfolio
• A conference call and a webcast are scheduled today, August 5, at 2:00 p.m. CET / 8:00 a.m. ET